These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33791916)

  • 21. Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study.
    Zhou HM; Zhan RJ; Chen X; Lin YF; Zhang SZ; Zheng H; Wang X; Huang MT; Xu CG; Liao XX; Tian T; Zhuang XD
    ESC Heart Fail; 2023 Feb; 10(1):322-333. PubMed ID: 36221795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
    Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
    Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2018 Mar; 20(3):483-490. PubMed ID: 29148144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
    Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
    Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
    Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett B; Shah SJ; Anand IS; Rouleau JL; Desai AS; Lewis EF; Vaduganathan M; Wang SY; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2019 Jul; 12(7):e006125. PubMed ID: 31220936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
    Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
    J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
    Zhu W; Wu Y; Zhou Y; Liang W; Xue R; Wu Z; Dong Y; Liu C
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):763-772. PubMed ID: 32583288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
    Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
    JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
    Shah SJ; Heitner JF; Sweitzer NK; Anand IS; Kim HY; Harty B; Boineau R; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Lewis EF; Markov V; O'Meara E; Kobulia B; Shaburishvili T; Solomon SD; Pitt B; Pfeffer MA; Li R
    Circ Heart Fail; 2013 Mar; 6(2):184-92. PubMed ID: 23258572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter SS; Shah SJ
    Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
    Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
    Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction.
    Belkin MN; Blair JE; Shah SJ; Alenghat FJ
    ESC Heart Fail; 2021 Oct; 8(5):3495-3503. PubMed ID: 34369088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction.
    Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Køber L; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    Clin Res Cardiol; 2021 Aug; 110(8):1234-1248. PubMed ID: 33301080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT.
    Ferreira JP; Rossello X; Pocock SJ; Rossignol P; Claggett BL; Rouleau JL; Solomon SD; Pitt B; Pfeffer MA; Zannad F
    Eur J Heart Fail; 2020 Sep; 22(9):1615-1624. PubMed ID: 32452128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.
    O'Neal WT; Sandesara PB; Samman-Tahhan A; Kelli HM; Hammadah M; Soliman EZ
    Eur J Prev Cardiol; 2017 Jul; 24(11):1212-1219. PubMed ID: 28482692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time-averaged cumulative blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: analysis from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
    Huang R; Wu R; Lin Y; Zhong X; Ye X; Zhuang X; Liao X
    J Hypertens; 2022 Oct; 40(10):1918-1926. PubMed ID: 36018222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
    Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
    Sperry BW; Hanna M; Shah SJ; Jaber WA; Spertus JA
    JACC Heart Fail; 2021 Nov; 9(11):795-802. PubMed ID: 34509404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.